Hybridoma technology is applied to induce a hybrid cell by fusing beta lymphocytes with myeloma cell. By employing this technology these hybrid cells obtain power to generate antibodies because of beta lymphocyte genetic components and also gain ability to multiply indefinitely as a consequence of involvement of myeloma cells. Hybrid cells propagate by employing Hybridoma technology that may be cultured in a laboratory or subcultured in a mouse bodily cavity. These hybrid cells produced monoclonal antibody and this process is point out as Hybridoma technology. The production of MAbs by using Hybridoma technology involves following steps:
- Immunization
- Cell fusion
- Selection of Hybridomas
- Screening
- Cloning and propagation
- Characterization and storage
Immunization
An suitable adjuvant is blended with microgram or milligram amounts of immunogen and injected at multiple site of the mouse at various times in a repetitious manners.
At times the mice is bled and examination for antibodies of purposed specificity is made. Highest concentration of antibodies are established after the mouse is immense with 2-3 individual delicate doses of antigen. At the point when concentration of antibody are most extreme the mouse is yielded and the spleen is taken. Then it is separated into individual spleenocyte by applying enzyme or instrumental process.
Lymphocytes of the spleen is separated from rest of the organelles by Density gradient centrifugation
Cell fusion
Thoroughly clean lymphocytes are blend with HGPRT deteriorative myeloma cells in this stage. Next the combination of the cells are disclosed to a strong concentration of PEG and unification is occur. The PGE Chuck out by washing and the cells are maintained In a well nurse medium. Three types of cells are found in the medium.
